KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Regeneron Pharmaceuticals (REGN) Current Leases (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Current Leases for 8 consecutive years, with $720.0 million as the latest value for Q1 2026.

For Q1 2026, Current Leases changed N/A year-over-year to $720.0 million; the TTM value through Mar 2026 reached $720.0 million, changed N/A, while the annual FY2021 figure was $719.7 million, N/A changed from the prior year.
Current Leases hit $720.0 million in Q1 2026 for Regeneron Pharmaceuticals, roughly flat from $719.7 million in the prior quarter.
Across five years, Current Leases topped out at $720.0 million in Q1 2026 and bottomed at $720.0 million in Q1 2026.